In short
This article discusses a clinical trial investigating the use of Verapamil Hydrochloride Ph. Eur. in adults with Type 1 diabetes mellitus (T1D). The study aims to explore the long-term effects of Verapamil SR therapy on preserving beta-cell function in T1D patients. The trial is designed as an open-label, multi-centre study, focusing on various aspects of diabetes management and potential benefits of this medication.
At a glance
- Study Type
- Open-label, multi-centre trial
- Participants
- Adults with Type 1 diabetes mellitus
- Medication
- Verapamil Hydrochloride Ph. Eur. (Verapamil SR)
- Dosage
- 360 mg orally once daily
- Duration
- 24 months
- Primary Objective
- Assess change in beta-cell function
- Secondary Objectives
- Monitor HbA1c changes, insulin requirements, hypoglycemic episodes, and safety
- Key Measurements
- C-peptide response, HbA1c levels, insulin dose, adverse events
Overview of the Clinical Trial
A new clinical trial is exploring the potential benefits of a medication called Verapamil Hydrochloride for people with Type 1 diabetes mellitus (T1D). This medication, also known by its brand name Half Securon SR, is being studied to see if it can help preserve the function of beta cells in the pancreas.
The trial is an open-label, multi-center study, which means that both the researchers and participants know which treatment is being given. It's designed to look at the long-term effects of Verapamil SR therapy on adults who have been recently diagnosed with Type 1 diabetes.
Purpose of the Study
The main goal of this study is to determine how Verapamil SR affects the function of beta cells in people with Type 1 diabetes. Beta cells are the cells in the pancreas that produce insulin, a hormone crucial for regulating blood sugar levels. In Type 1 diabetes, these cells are mistakenly attacked and destroyed by the body's immune system.
Specifically, the researchers want to measure:
- Changes in beta cell function over time, measured by C-peptide response to a mixed-meal tolerance test (MMTT). C-peptide is a substance produced along with insulin and can indicate how much insulin the body is making.
- Changes in HbA1c levels, which show average blood sugar control over the past 2-3 months.
- Changes in insulin requirements over time.
- The number of severe hypoglycemic (low blood sugar) episodes and ketoacidosis (a serious complication of diabetes) episodes.
Who Can Participate?
The study is looking for adults (18 years or older) who have been recently diagnosed with Type 1 diabetes. Participants must have a certain level of beta cell function remaining, as indicated by their fasting C-peptide levels.
However, there are several conditions that would prevent someone from participating, including:
- Pregnancy or plans to become pregnant during the study period
- Certain heart conditions
- Current use of beta-blockers or calcium channel blockers
- Liver or kidney problems
- Known allergy to Verapamil SR
Treatment Details
Participants in the study will receive 360 mg of Verapamil SR (Half Securon SR) orally once daily for 24 months. The dose will be gradually increased over the first three weeks, starting from 120 mg and reaching the full dose of 360 mg.
What Will Be Measured?
Throughout the study, researchers will measure several factors to assess the effectiveness and safety of the treatment:
- Beta cell function: This will be measured using a mixed-meal tolerance test (MMTT), which involves drinking a special drink and then measuring C-peptide levels in the blood.
- Blood sugar control: HbA1c levels will be measured at regular intervals.
- Insulin needs: The amount of insulin required daily will be tracked.
- Safety measures: This includes monitoring vital signs, performing ECGs (heart tests), and checking laboratory safety parameters.
Safety Considerations
The study will closely monitor participants for any side effects or safety concerns. This includes tracking:
- Episodes of severe hypoglycemia (dangerously low blood sugar)
- Episodes of diabetic ketoacidosis (a serious complication where the body produces high levels of blood acids called ketones)
- Any other adverse events
Potential Implications for Type 1 Diabetes Treatment
If successful, this study could open up new treatment possibilities for people with Type 1 diabetes. By preserving beta cell function, Verapamil SR might help people with T1D maintain some natural insulin production, potentially leading to better blood sugar control and reduced risk of complications.
However, it's important to remember that this is still a research study. More evidence is needed before Verapamil SR could be recommended as a standard treatment for Type 1 diabetes.